388 related articles for article (PubMed ID: 31965181)
1. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
2. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
4. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
5. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
6. BNA
Manning KS; Rao AN; Castro M; Cooper TA
ACS Chem Biol; 2017 Oct; 12(10):2503-2509. PubMed ID: 28853853
[TBL] [Abstract][Full Text] [Related]
7. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
[TBL] [Abstract][Full Text] [Related]
8. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
9. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice.
Lo Scrudato M; Poulard K; Sourd C; Tomé S; Klein AF; Corre G; Huguet A; Furling D; Gourdon G; Buj-Bello A
Mol Ther; 2019 Aug; 27(8):1372-1388. PubMed ID: 31253581
[TBL] [Abstract][Full Text] [Related]
10. FISH Protocol for Myotonic Dystrophy Type 1 Cells.
Klein AF; Arandel L; Marie J; Furling D
Methods Mol Biol; 2020; 2056():203-215. PubMed ID: 31586350
[TBL] [Abstract][Full Text] [Related]
11. Reversible cardiac disease features in an inducible CUG repeat RNA-expressing mouse model of myotonic dystrophy.
Rao AN; Campbell HM; Guan X; Word TA; Wehrens XH; Xia Z; Cooper TA
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33497365
[TBL] [Abstract][Full Text] [Related]
12. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients.
Botta A; Rinaldi F; Catalli C; Vergani L; Bonifazi E; Romeo V; Loro E; Viola A; Angelini C; Novelli G
J Med Genet; 2008 Oct; 45(10):639-46. PubMed ID: 18611984
[TBL] [Abstract][Full Text] [Related]
13. An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I.
López-Martínez A; Soblechero-Martín P; de-la-Puente-Ovejero L; Nogales-Gadea G; Arechavala-Gomeza V
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32971903
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
[TBL] [Abstract][Full Text] [Related]
15. Expanded CUG repeats in
van Cruchten RTP; Wieringa B; Wansink DG
RNA; 2019 Apr; 25(4):481-495. PubMed ID: 30700578
[TBL] [Abstract][Full Text] [Related]
16. RNA-mediated therapies in myotonic dystrophy.
Overby SJ; Cerro-Herreros E; Llamusi B; Artero R
Drug Discov Today; 2018 Dec; 23(12):2013-2022. PubMed ID: 30086404
[TBL] [Abstract][Full Text] [Related]
17. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts.
Langlois MA; Lee NS; Rossi JJ; Puymirat J
Mol Ther; 2003 May; 7(5 Pt 1):670-80. PubMed ID: 12718910
[TBL] [Abstract][Full Text] [Related]
18. Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy.
Tanner MK; Tang Z; Thornton CA
Nucleic Acids Res; 2021 Feb; 49(4):2240-2254. PubMed ID: 33503262
[TBL] [Abstract][Full Text] [Related]
19. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
[TBL] [Abstract][Full Text] [Related]
20. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
